Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133879) titled 'Analysis of factors influencing infliximab efficacy for Crohn's disease and construction and validation of precision pharmaceutical monitoring pathways' on Oct. 9.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shanghai Baoshan District Dachang Hospital
Condition:
Crohn's disease
Intervention:
Experimental group:Receive clinical pharmacy monitoring pathways
Control group:N/A
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-15
Target Sample Size: Experimental group:103;Control group:103;Observation group:300;
Countries of Recruitment:
China
...